ArticleJournal of neuro-oncology2026
Virus-like particle vaccine targeting meningeal lymphatic vessels via intradural delivery activates anti-glioma immunity.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a lethal brain tumor with a poor prognosis, largely due to an immunosuppressive microenvironment and the blood-brain barrier. The discovery of meningeal lymphatic vessels (MLVs) offers a new avenue for central nervous system immune engagement.
objectiveWe aimed to develop a novel immunotherapy by combining a virus-like particle (VLP) nanovaccine with intradural administration to activate meningeal immunity against GBM.
methodsA virus-like particle (VLP)-based nanovaccine (OVA-HBc) was engineered and characterized. Its efficacy was evaluated in an orthotopic GL261-OVA-Luc glioma mouse model, comparing intradural delivery with intravenous and intranasal routes through tumor imaging and survival analysis.
resultsOVA-HBc formed stable nanoparticles (~ 36 nm), was non-toxic, and potently activated dendritic cells in vitro. In vivo, only intradural administration of OVA-HBc induced marked tumor regression and was associated with prolonged survival (over 60% survival at 60 days), showing potential advantages over systemic routes. This effect is likely mediated by precise meningeal targeting and efficient antigen drainage via MLVs.
conclusionThis study suggests that intradural delivery of HBc VLPs can engage MLVs to activate anti-glioma immunity in a mouse model. This approach offers a potential strategy to bypass certain central delivery barriers, representing a preliminary framework for GBM immunotherapy.
Indexed as
Identifiers
42101546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.